# Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

> **NCT02997956** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tocilizumab
- **PROCEDURE:** Transcatheter Arterial Chemoembolization

## Key facts

- **NCT ID:** NCT02997956
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07
- **Primary completion:** 2020-07
- **Final completion:** 2022-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** funding issues
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997956, "Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02997956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*